8-K: IN8bio Unveils Novel Gamma-Delta T Cell Engager Platform Targeting Oncology and Autoimmune Diseases

IN8bio announces a new gamma-delta T cell engager platform, INB-600, designed to enhance T cell expansion and target B cells for oncology and autoimmune applications, with its lead candidate INB-619 showing promising preclinical results.

Summary

• IN8bio has announced its new gamma-delta (gd) T cell engager (TCE) platform, INB-600, aimed at treating oncology and autoimmune diseases.
• The platform addresses the limitation of current gd TCEs by enhancing gd T cell expansion.
• INB-619, the platform's first candidate, targets CD19, a marker found on B cells, which are implicated in leukemias, lymphomas, and autoimmune diseases.
• Preclinical models show that INB-619 eradicates B cells and sustains depletion as gd T cells expand up to 450-fold.
• The platform expands both Vd1+ and Vd2+ T cell subsets, potentially leading to longer-lasting immune responses.
• gd T cells secrete lower levels of IL-6, potentially reducing the risk of cytokine release syndrome (CRS) and neurotoxicity (ICANs) compared to traditional TCEs and CAR-T therapies.
• IN8bio plans to conduct preclinical studies of INB-619 and seek partners to support future IND-enabling trials.

Sentiment

Score: 8

Explanation: The announcement is positive due to the unveiling of a novel platform with promising preclinical data and a focus on addressing key limitations of existing immunotherapies. The potential for improved safety and efficacy contributes to the positive sentiment.

Positives

• The INB-600 platform addresses the issue of insufficient numbers of gd T cell effector cells, a major limitation of current gd TCEs.
• INB-619 has shown rapid and sustained B-cell depletion in preclinical models.
• The platform's ability to expand both Vd1+ and Vd2+ T cell subsets could lead to deeper B cell depletion and longer-lasting immune responses.
• Lower IL-6 secretion by gd T cells may reduce the risk of CRS and ICANs, improving safety and tolerability compared to traditional TCEs and CAR-T therapies.
• IN8bio has not observed any CRS or neurotoxicities in any of its ongoing gd T cell clinical programs to date.

Risks

• The success of the INB-600 platform and INB-619 depends on the outcomes of preclinical studies and future clinical trials.
• IN8bio's ability to advance the platform depends on securing partnerships to support IND-enabling trials.
• Forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial commencement, patient enrollment, and regulatory approvals.
• There is a risk that IN8bio may be unable to raise additional capital, which could impact its development programs.

Future Outlook

IN8bio plans to evaluate INB-619 in preclinical studies and seek potential partners to support future IND-enabling trials, with the goal of advancing next-generation gd cell-based immunotherapies.

Management Comments

• William Ho, CEO of IN8bio, stated that the INB-600 platform aims to address the unmet need for a therapy that provides deep B cell depletion, ease of delivery, and improved safety and tolerability.
• Ho believes the platform combines exceptional preclinical potency with broad immune surveillance, potentially avoiding the dangerous side effects of existing approaches.

Industry Context

This announcement positions IN8bio in the competitive field of immunotherapy, specifically targeting the limitations of existing TCEs and CAR-T therapies by leveraging the unique properties of gamma-delta T cells. The focus on reducing cytokine release syndrome (CRS) and neurotoxicity (ICANs) aligns with the industry's efforts to improve the safety profiles of these treatments.

Comparison to Industry Standards

• Traditional TCEs, such as those targeting CD3, have demonstrated strong target killing abilities but often have severe limitations, including the potential to drive T cells to exhaustion and induce severe toxicities such as CRS and ICANs.
• CAR-T therapies have shown efficacy in certain cancers, but are limited by toxicities such as CRS and ICANs.
• Companies like Amgen (with Blincyto) and Roche (with Columvi) have developed CD3-targeting TCEs, but these can be associated with significant toxicities.
• IN8bio's approach aims to improve upon these existing therapies by utilizing gamma-delta T cells, which naturally secrete lower levels of inflammatory cytokines, potentially reducing the risk of CRS and ICANs.

Stakeholder Impact

• Shareholders may react positively to the announcement of a new platform with potential for improved safety and efficacy in cancer and autoimmune disease treatments.
• Employees may be motivated by the company's focus on innovation and its mission to eliminate cancer.
• Patients may benefit from the development of new therapies with reduced side effects.
• Potential partners may be interested in collaborating with IN8bio to support the development of INB-619 and the INB-600 platform.

Next Steps

• IN8bio plans to evaluate INB-619 in preclinical studies.
• IN8bio will seek potential partners to support future IND-enabling trials.

Key Dates